Scynexis (SCYX) Change in Account Payables (2023 - 2026)
Scynexis' (SCYX) quarterly Change in Account Payables came in at -$472000.0 in Q2 2026, down 124.69% on a YoY basis from $1.9 million in Q2 2025, and down 152.1% quarter-over-quarter from $906000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Change in Account Payables (2023 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Change in Account Payables for 4 consecutive years, with -$472000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Account Payables fell 124.69% year-over-year to -$472000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.5 million (down 527.37% YoY), and the FY2025 full-year result was -$2.2 million, up 15.7% from the prior year.
- Change in Account Payables eased to -$472000.0 in Q2 2026 per SCYX's latest filing, from $906000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.6 million in Q4 2023 and bottomed at -$3.6 million in Q2 2024.
- Historically, Change in Account Payables has averaged -$234142.9 across 4 years, with a median of -$303000.0 in 2024.
- The widest YoY moves for Change in Account Payables: up 15175.0% in 2024, down 650.0% in 2024.
- Over 4 years, Change in Account Payables stood at $3.6 million in 2023, then sank by 113.37% to -$484000.0 in 2024, then slumped by 156.61% to -$1.2 million in 2025, then jumped by 62.0% to -$472000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$472000.0, $906000.0, and -$1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 7.11 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -472,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -472,000.00 |
| Mar 31, 2026 | 906,000.00 |
| Dec 31, 2025 | -1.24 Mn |
| Sep 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | -199,000.00 |
| Dec 31, 2024 | -484,000.00 |
| Sep 30, 2024 | -407,000.00 |
| Jun 30, 2024 | -3.57 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | -2.51 Mn |
| Mar 31, 2023 | -12,000.00 |